ES2689700T3 - Intervención nutricional para mejorar la función y resistencia muscular - Google Patents

Intervención nutricional para mejorar la función y resistencia muscular Download PDF

Info

Publication number: ES2689700T3
Authority: ES; Spain
Prior art keywords: vitamin; hmb; muscle; vitd3; endurance
Prior art date: 2008-12-09
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Active

Application number

ES09832494.0T

Other languages

English (en)

Spanish (es)

Inventor

John Rathmacher

John Fuller

Shawn Baier

Steven Nissen

Naji Abumrad

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Metabolic Technologies LLC

Original Assignee

Metabolic Technologies LLC

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-12-09

Filing date

2009-12-09

Publication date

2018-11-15

2009-12-09 Application filed by Metabolic Technologies LLC filed Critical Metabolic Technologies LLC

2018-11-15 Application granted granted Critical

2018-11-15 Publication of ES2689700T3 publication Critical patent/ES2689700T3/es

Status Active legal-status Critical Current

2029-12-09 Anticipated expiration legal-status Critical

Links

230000004220 muscle function Effects 0.000 title claims description 21
235000021196 dietary intervention Nutrition 0.000 title description 2
QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims abstract description 141
239000011710 vitamin D Substances 0.000 claims abstract description 140
229940046008 vitamin d Drugs 0.000 claims abstract description 140
229930003316 Vitamin D Natural products 0.000 claims abstract description 137
235000019166 vitamin D Nutrition 0.000 claims abstract description 137
150000003710 vitamin D derivatives Chemical class 0.000 claims abstract description 137
239000000203 mixture Substances 0.000 claims abstract description 61
230000036765 blood level Effects 0.000 claims abstract description 12
210000003205 muscle Anatomy 0.000 claims description 50
230000001965 increasing effect Effects 0.000 claims description 22
241001465754 Metazoa Species 0.000 claims description 17
238000001990 intravenous administration Methods 0.000 claims description 10
239000002253 acid Substances 0.000 claims description 8
235000013305 food Nutrition 0.000 claims description 7
150000003839 salts Chemical class 0.000 claims description 6
235000005282 vitamin D3 Nutrition 0.000 claims description 6
239000011647 vitamin D3 Substances 0.000 claims description 6
159000000007 calcium salts Chemical class 0.000 claims description 5
QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 claims description 5
150000002596 lactones Chemical class 0.000 claims description 4
MECHNRXZTMCUDQ-RKHKHRCZSA-N vitamin D2 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)/C=C/[C@H](C)C(C)C)=C\C=C1\C[C@@H](O)CCC1=C MECHNRXZTMCUDQ-RKHKHRCZSA-N 0.000 claims description 4
229940021056 vitamin d3 Drugs 0.000 claims description 4
MECHNRXZTMCUDQ-UHFFFAOYSA-N Vitamin D2 Natural products C1CCC2(C)C(C(C)C=CC(C)C(C)C)CCC2C1=CC=C1CC(O)CCC1=C MECHNRXZTMCUDQ-UHFFFAOYSA-N 0.000 claims description 3
229960002061 ergocalciferol Drugs 0.000 claims description 3
150000002148 esters Chemical class 0.000 claims description 3
235000001892 vitamin D2 Nutrition 0.000 claims description 3
239000011653 vitamin D2 Substances 0.000 claims description 3
150000001844 chromium Chemical class 0.000 claims description 2
150000001875 compounds Chemical class 0.000 claims description 2
125000004494 ethyl ester group Chemical group 0.000 claims description 2
159000000003 magnesium salts Chemical class 0.000 claims description 2
XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 claims description 2
159000000000 sodium salts Chemical class 0.000 claims description 2
125000004492 methyl ester group Chemical group 0.000 claims 1
AXFYFNCPONWUHW-UHFFFAOYSA-N 3-hydroxyisovaleric acid Chemical compound CC(C)(O)CC(O)=O AXFYFNCPONWUHW-UHFFFAOYSA-N 0.000 abstract 4
AXFYFNCPONWUHW-UHFFFAOYSA-M 3-hydroxyisovalerate Chemical compound CC(C)(O)CC([O-])=O AXFYFNCPONWUHW-UHFFFAOYSA-M 0.000 description 168
238000000034 method Methods 0.000 description 30
238000011282 treatment Methods 0.000 description 25
230000000694 effects Effects 0.000 description 22
KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 21
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 21
102000009310 vitamin D receptors Human genes 0.000 description 21
108050000156 vitamin D receptors Proteins 0.000 description 21
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 20
235000018102 proteins Nutrition 0.000 description 20
102000004169 proteins and genes Human genes 0.000 description 20
108090000623 proteins and genes Proteins 0.000 description 20
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 19
230000017854 proteolysis Effects 0.000 description 19
230000006872 improvement Effects 0.000 description 18
239000013589 supplement Substances 0.000 description 17
ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 14
238000001243 protein synthesis Methods 0.000 description 14
230000014616 translation Effects 0.000 description 14
210000002966 serum Anatomy 0.000 description 13
206010047626 Vitamin D Deficiency Diseases 0.000 description 12
238000004458 analytical method Methods 0.000 description 12
239000011575 calcium Substances 0.000 description 12
230000007423 decrease Effects 0.000 description 12
230000006870 function Effects 0.000 description 12
238000005259 measurement Methods 0.000 description 12
210000004027 cell Anatomy 0.000 description 11
230000009469 supplementation Effects 0.000 description 11
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 10
108020004414 DNA Proteins 0.000 description 10
235000001014 amino acid Nutrition 0.000 description 10
150000001413 amino acids Chemical class 0.000 description 10
229910052791 calcium Inorganic materials 0.000 description 10
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 10
210000003127 knee Anatomy 0.000 description 10
230000002195 synergetic effect Effects 0.000 description 10
230000004913 activation Effects 0.000 description 9
210000000663 muscle cell Anatomy 0.000 description 9
230000037361 pathway Effects 0.000 description 9
238000012360 testing method Methods 0.000 description 9
235000020799 vitamin D status Nutrition 0.000 description 9
239000004472 Lysine Substances 0.000 description 8
210000004369 blood Anatomy 0.000 description 8
239000008280 blood Substances 0.000 description 8
239000004475 Arginine Substances 0.000 description 7
ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 7
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 7
235000009697 arginine Nutrition 0.000 description 7
230000014509 gene expression Effects 0.000 description 7
230000003993 interaction Effects 0.000 description 7
238000012549 training Methods 0.000 description 7
BKAJNAXTPSGJCU-UHFFFAOYSA-N 4-methyl-2-oxopentanoic acid Chemical group CC(C)CC(=O)C(O)=O BKAJNAXTPSGJCU-UHFFFAOYSA-N 0.000 description 6
230000015572 biosynthetic process Effects 0.000 description 6
210000000170 cell membrane Anatomy 0.000 description 6
230000007246 mechanism Effects 0.000 description 6
210000002700 urine Anatomy 0.000 description 6
102100026992 Dermcidin Human genes 0.000 description 5
101000911659 Homo sapiens Dermcidin Proteins 0.000 description 5
241000700159 Rattus Species 0.000 description 5
230000037396 body weight Effects 0.000 description 5
235000012000 cholesterol Nutrition 0.000 description 5
201000010099 disease Diseases 0.000 description 5
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
230000036541 health Effects 0.000 description 5
230000004060 metabolic process Effects 0.000 description 5
230000003387 muscular Effects 0.000 description 5
210000001519 tissue Anatomy 0.000 description 5
102000003982 Parathyroid hormone Human genes 0.000 description 4
108090000445 Parathyroid hormone Proteins 0.000 description 4
108010065917 TOR Serine-Threonine Kinases Proteins 0.000 description 4
102000013530 TOR Serine-Threonine Kinases Human genes 0.000 description 4
230000008901 benefit Effects 0.000 description 4
210000000988 bone and bone Anatomy 0.000 description 4
239000002775 capsule Substances 0.000 description 4
SWXVUIWOUIDPGS-UHFFFAOYSA-N diacetone alcohol Chemical compound CC(=O)CC(C)(C)O SWXVUIWOUIDPGS-UHFFFAOYSA-N 0.000 description 4
235000015872 dietary supplement Nutrition 0.000 description 4
239000000835 fiber Substances 0.000 description 4
238000000338 in vitro Methods 0.000 description 4
239000002207 metabolite Substances 0.000 description 4
239000000199 parathyroid hormone Substances 0.000 description 4
229960001319 parathyroid hormone Drugs 0.000 description 4
230000026731 phosphorylation Effects 0.000 description 4
238000006366 phosphorylation reaction Methods 0.000 description 4
230000004044 response Effects 0.000 description 4
238000003786 synthesis reaction Methods 0.000 description 4
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
-1 HMB lactones Chemical class 0.000 description 3
241000282412 Homo Species 0.000 description 3
102100034170 Interferon-induced, double-stranded RNA-activated protein kinase Human genes 0.000 description 3
241000124008 Mammalia Species 0.000 description 3
108010074633 Mixed Function Oxygenases Proteins 0.000 description 3
102000008109 Mixed Function Oxygenases Human genes 0.000 description 3
241001529936 Murinae Species 0.000 description 3
208000010428 Muscle Weakness Diseases 0.000 description 3
206010028372 Muscular weakness Diseases 0.000 description 3
206010028980 Neoplasm Diseases 0.000 description 3
102000003923 Protein Kinase C Human genes 0.000 description 3
108090000315 Protein Kinase C Proteins 0.000 description 3
230000002238 attenuated effect Effects 0.000 description 3
238000004113 cell culture Methods 0.000 description 3
238000006243 chemical reaction Methods 0.000 description 3
UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 3
229960003957 dexamethasone Drugs 0.000 description 3
230000003828 downregulation Effects 0.000 description 3
239000003937 drug carrier Substances 0.000 description 3
230000003834 intracellular effect Effects 0.000 description 3
210000002414 leg Anatomy 0.000 description 3
210000003141 lower extremity Anatomy 0.000 description 3
210000003098 myoblast Anatomy 0.000 description 3
230000003647 oxidation Effects 0.000 description 3
238000007254 oxidation reaction Methods 0.000 description 3
230000003389 potentiating effect Effects 0.000 description 3
239000000047 product Substances 0.000 description 3
230000004844 protein turnover Effects 0.000 description 3
208000007442 rickets Diseases 0.000 description 3
238000007619 statistical method Methods 0.000 description 3
GMRQFYUYWCNGIN-UHFFFAOYSA-N 1,25-Dihydroxy-vitamin D3' Natural products C1CCC2(C)C(C(CCCC(C)(C)O)C)CCC2C1=CC=C1CC(O)CC(O)C1=C GMRQFYUYWCNGIN-UHFFFAOYSA-N 0.000 description 2
208000030507 AIDS Diseases 0.000 description 2
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
102000004420 Creatine Kinase Human genes 0.000 description 2
108010042126 Creatine kinase Proteins 0.000 description 2
102000004190 Enzymes Human genes 0.000 description 2
108090000790 Enzymes Proteins 0.000 description 2
102000034615 Glial cell line-derived neurotrophic factor Human genes 0.000 description 2
108091010837 Glial cell line-derived neurotrophic factor Proteins 0.000 description 2
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
102000043136 MAP kinase family Human genes 0.000 description 2
108091054455 MAP kinase family Proteins 0.000 description 2
241000699670 Mus sp. Species 0.000 description 2
208000029549 Muscle injury Diseases 0.000 description 2
108020005497 Nuclear hormone receptor Proteins 0.000 description 2
229910019142 PO4 Inorganic materials 0.000 description 2
OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
102000001253 Protein Kinase Human genes 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
238000010521 absorption reaction Methods 0.000 description 2
150000007513 acids Chemical class 0.000 description 2
238000000540 analysis of variance Methods 0.000 description 2
YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
238000003556 assay Methods 0.000 description 2
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
230000033228 biological regulation Effects 0.000 description 2
229960005084 calcitriol Drugs 0.000 description 2
GMRQFYUYWCNGIN-NKMMMXOESA-N calcitriol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-NKMMMXOESA-N 0.000 description 2
230000003913 calcium metabolism Effects 0.000 description 2
201000011510 cancer Diseases 0.000 description 2
230000000875 corresponding effect Effects 0.000 description 2
230000003247 decreasing effect Effects 0.000 description 2
230000002950 deficient Effects 0.000 description 2
230000001419 dependent effect Effects 0.000 description 2
238000013461 design Methods 0.000 description 2
235000005911 diet Nutrition 0.000 description 2
235000018823 dietary intake Nutrition 0.000 description 2
230000004069 differentiation Effects 0.000 description 2
239000002158 endotoxin Substances 0.000 description 2
230000029142 excretion Effects 0.000 description 2
238000004817 gas chromatography Methods 0.000 description 2
230000008571 general function Effects 0.000 description 2
230000003054 hormonal effect Effects 0.000 description 2
230000033444 hydroxylation Effects 0.000 description 2
238000005805 hydroxylation reaction Methods 0.000 description 2
238000010348 incorporation Methods 0.000 description 2
238000001802 infusion Methods 0.000 description 2
210000003734 kidney Anatomy 0.000 description 2
229920006008 lipopolysaccharide Polymers 0.000 description 2
239000007788 liquid Substances 0.000 description 2
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
230000004048 modification Effects 0.000 description 2
238000012986 modification Methods 0.000 description 2
102000006255 nuclear receptors Human genes 0.000 description 2
108020004017 nuclear receptors Proteins 0.000 description 2
235000016709 nutrition Nutrition 0.000 description 2
210000000056 organ Anatomy 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
239000010452 phosphate Substances 0.000 description 2
229910052698 phosphorus Inorganic materials 0.000 description 2
239000011574 phosphorus Substances 0.000 description 2
230000006950 reactive oxygen species formation Effects 0.000 description 2
102000005962 receptors Human genes 0.000 description 2
108020003175 receptors Proteins 0.000 description 2
230000002829 reductive effect Effects 0.000 description 2
230000008929 regeneration Effects 0.000 description 2
238000011069 regeneration method Methods 0.000 description 2
238000011160 research Methods 0.000 description 2
238000012552 review Methods 0.000 description 2
210000001908 sarcoplasmic reticulum Anatomy 0.000 description 2
210000004116 schwann cell Anatomy 0.000 description 2
210000002363 skeletal muscle cell Anatomy 0.000 description 2
239000000758 substrate Substances 0.000 description 2
230000000153 supplemental effect Effects 0.000 description 2
231100000331 toxic Toxicity 0.000 description 2
230000002588 toxic effect Effects 0.000 description 2
230000032258 transport Effects 0.000 description 2
230000006663 ubiquitin-proteasome pathway Effects 0.000 description 2
230000002485 urinary effect Effects 0.000 description 2
229940088594 vitamin Drugs 0.000 description 2
229930003231 vitamin Natural products 0.000 description 2
235000013343 vitamin Nutrition 0.000 description 2
239000011782 vitamin Substances 0.000 description 2
150000003722 vitamin derivatives Chemical class 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
CABVTRNMFUVUDM-VRHQGPGLSA-N (3S)-3-hydroxy-3-methylglutaryl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C[C@@](O)(CC(O)=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 CABVTRNMFUVUDM-VRHQGPGLSA-N 0.000 description 1
JWUBBDSIWDLEOM-XHQRYOPUSA-N (3e)-3-[(2e)-2-[1-(6-hydroxy-6-methylheptan-2-yl)-7a-methyl-2,3,3a,5,6,7-hexahydro-1h-inden-4-ylidene]ethylidene]-4-methylidenecyclohexan-1-ol Chemical compound C1CCC2(C)C(C(CCCC(C)(C)O)C)CCC2\C1=C\C=C1/CC(O)CCC1=C JWUBBDSIWDLEOM-XHQRYOPUSA-N 0.000 description 1
YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 1
108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
101710191936 70 kDa protein Proteins 0.000 description 1
102000005862 Angiotensin II Human genes 0.000 description 1
101800000733 Angiotensin-2 Proteins 0.000 description 1
208000006820 Arthralgia Diseases 0.000 description 1
206010003694 Atrophy Diseases 0.000 description 1
208000010392 Bone Fractures Diseases 0.000 description 1
206010006895 Cachexia Diseases 0.000 description 1
235000021318 Calcifediol Nutrition 0.000 description 1
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
102000014914 Carrier Proteins Human genes 0.000 description 1
102000053602 DNA Human genes 0.000 description 1
102100022466 Eukaryotic translation initiation factor 4E-binding protein 1 Human genes 0.000 description 1
108050000946 Eukaryotic translation initiation factor 4E-binding protein 1 Proteins 0.000 description 1
206010017076 Fracture Diseases 0.000 description 1
108091006027 G proteins Proteins 0.000 description 1
102000030782 GTP binding Human genes 0.000 description 1
108091000058 GTP-Binding Proteins 0.000 description 1
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 description 1
238000012404 In vitro experiment Methods 0.000 description 1
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
229930064664 L-arginine Natural products 0.000 description 1
235000014852 L-arginine Nutrition 0.000 description 1
229930182816 L-glutamine Natural products 0.000 description 1
108010028554 LDL Cholesterol Proteins 0.000 description 1
241000699666 Mus <mouse, genus> Species 0.000 description 1
208000021642 Muscular disease Diseases 0.000 description 1
201000009623 Myopathy Diseases 0.000 description 1
101150064037 NGF gene Proteins 0.000 description 1
108010025020 Nerve Growth Factor Proteins 0.000 description 1
102000007072 Nerve Growth Factors Human genes 0.000 description 1
102000012738 S100 Calcium Binding Protein G Human genes 0.000 description 1
108010079423 S100 Calcium Binding Protein G Proteins 0.000 description 1
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
239000005708 Sodium hypochlorite Substances 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 1
102000040945 Transcription factor Human genes 0.000 description 1
108091023040 Transcription factor Proteins 0.000 description 1
108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
102100040247 Tumor necrosis factor Human genes 0.000 description 1
206010054094 Tumour necrosis Diseases 0.000 description 1
108091000117 Tyrosine 3-Monooxygenase Proteins 0.000 description 1
102000048218 Tyrosine 3-monooxygenases Human genes 0.000 description 1
208000027418 Wounds and injury Diseases 0.000 description 1
MMWCIQZXVOZEGG-HOZKJCLWSA-N [(1S,2R,3S,4S,5R,6S)-2,3,5-trihydroxy-4,6-diphosphonooxycyclohexyl] dihydrogen phosphate Chemical compound O[C@H]1[C@@H](O)[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](O)[C@H]1OP(O)(O)=O MMWCIQZXVOZEGG-HOZKJCLWSA-N 0.000 description 1
238000009825 accumulation Methods 0.000 description 1
WDJHALXBUFZDSR-UHFFFAOYSA-M acetoacetate Chemical compound CC(=O)CC([O-])=O WDJHALXBUFZDSR-UHFFFAOYSA-M 0.000 description 1
230000009471 action Effects 0.000 description 1
239000012190 activator Substances 0.000 description 1
230000009056 active transport Effects 0.000 description 1
230000002411 adverse Effects 0.000 description 1
230000032683 aging Effects 0.000 description 1
235000004279 alanine Nutrition 0.000 description 1
229910052783 alkali metal Inorganic materials 0.000 description 1
229950006323 angiotensin ii Drugs 0.000 description 1
210000003423 ankle Anatomy 0.000 description 1
230000006907 apoptotic process Effects 0.000 description 1
229940114079 arachidonic acid Drugs 0.000 description 1
235000021342 arachidonic acid Nutrition 0.000 description 1
229960005070 ascorbic acid Drugs 0.000 description 1
235000010323 ascorbic acid Nutrition 0.000 description 1
239000011668 ascorbic acid Substances 0.000 description 1
238000003149 assay kit Methods 0.000 description 1
230000037444 atrophy Effects 0.000 description 1
230000003305 autocrine Effects 0.000 description 1
230000035578 autophosphorylation Effects 0.000 description 1
239000002585 base Substances 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
230000027455 binding Effects 0.000 description 1
108091008324 binding proteins Proteins 0.000 description 1
230000036772 blood pressure Effects 0.000 description 1
230000037180 bone health Effects 0.000 description 1
235000021152 breakfast Nutrition 0.000 description 1
239000001110 calcium chloride Substances 0.000 description 1
229910001628 calcium chloride Inorganic materials 0.000 description 1
AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
239000000920 calcium hydroxide Substances 0.000 description 1
229910001861 calcium hydroxide Inorganic materials 0.000 description 1
230000003185 calcium uptake Effects 0.000 description 1
244000309466 calf Species 0.000 description 1
239000000969 carrier Substances 0.000 description 1
230000001925 catabolic effect Effects 0.000 description 1
230000021164 cell adhesion Effects 0.000 description 1
230000024245 cell differentiation Effects 0.000 description 1
230000003915 cell function Effects 0.000 description 1
230000004663 cell proliferation Effects 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
230000008859 change Effects 0.000 description 1
238000011284 combination treatment Methods 0.000 description 1
230000000295 complement effect Effects 0.000 description 1
238000012937 correction Methods 0.000 description 1
230000002596 correlated effect Effects 0.000 description 1
238000002425 crystallisation Methods 0.000 description 1
230000008025 crystallization Effects 0.000 description 1
230000006378 damage Effects 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
230000018044 dehydration Effects 0.000 description 1
238000006297 dehydration reaction Methods 0.000 description 1
238000001514 detection method Methods 0.000 description 1
238000011161 development Methods 0.000 description 1
230000018109 developmental process Effects 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
230000037213 diet Effects 0.000 description 1
230000000378 dietary effect Effects 0.000 description 1
230000008034 disappearance Effects 0.000 description 1
PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 1
238000009547 dual-energy X-ray absorptiometry Methods 0.000 description 1
230000004795 endocrine process Effects 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
230000002708 enhancing effect Effects 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
239000003797 essential amino acid Substances 0.000 description 1
235000020776 essential amino acid Nutrition 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
235000013861 fat-free Nutrition 0.000 description 1
239000008103 glucose Substances 0.000 description 1
235000013922 glutamic acid Nutrition 0.000 description 1
239000004220 glutamic acid Substances 0.000 description 1
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
239000003102 growth factor Substances 0.000 description 1
231100000508 hormonal effect Toxicity 0.000 description 1
230000028993 immune response Effects 0.000 description 1
230000001771 impaired effect Effects 0.000 description 1
238000011065 in-situ storage Methods 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
238000013101 initial test Methods 0.000 description 1
208000014674 injury Diseases 0.000 description 1
230000000968 intestinal effect Effects 0.000 description 1
230000003189 isokinetic effect Effects 0.000 description 1
239000003446 ligand Substances 0.000 description 1
150000002632 lipids Chemical class 0.000 description 1
108010022197 lipoprotein cholesterol Proteins 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
230000033001 locomotion Effects 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
239000000463 material Substances 0.000 description 1
108020004999 messenger RNA Proteins 0.000 description 1
238000010197 meta-analysis Methods 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
229910052751 metal Inorganic materials 0.000 description 1
239000002184 metal Substances 0.000 description 1
230000009456 molecular mechanism Effects 0.000 description 1
230000004973 motor coordination Effects 0.000 description 1
238000001964 muscle biopsy Methods 0.000 description 1
230000004118 muscle contraction Effects 0.000 description 1
210000002464 muscle smooth vascular Anatomy 0.000 description 1
210000001577 neostriatum Anatomy 0.000 description 1
230000001537 neural effect Effects 0.000 description 1
230000004770 neurodegeneration Effects 0.000 description 1
208000015122 neurodegenerative disease Diseases 0.000 description 1
210000004498 neuroglial cell Anatomy 0.000 description 1
210000000715 neuromuscular junction Anatomy 0.000 description 1
230000007514 neuronal growth Effects 0.000 description 1
239000003900 neurotrophic factor Substances 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
231100000957 no side effect Toxicity 0.000 description 1
230000009871 nonspecific binding Effects 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
230000035764 nutrition Effects 0.000 description 1
102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 description 1
108010068338 p38 Mitogen-Activated Protein Kinases Proteins 0.000 description 1
150000003904 phospholipids Chemical class 0.000 description 1
230000036314 physical performance Effects 0.000 description 1
239000006187 pill Substances 0.000 description 1
238000013105 post hoc analysis Methods 0.000 description 1
239000000843 powder Substances 0.000 description 1
239000002243 precursor Substances 0.000 description 1
238000004321 preservation Methods 0.000 description 1
230000008569 process Effects 0.000 description 1
230000035755 proliferation Effects 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
230000001737 promoting effect Effects 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
238000002731 protein assay Methods 0.000 description 1
108060006633 protein kinase Proteins 0.000 description 1
230000022558 protein metabolic process Effects 0.000 description 1
239000003642 reactive oxygen metabolite Substances 0.000 description 1
230000009467 reduction Effects 0.000 description 1
230000018350 regulation of phosphate metabolic process Effects 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
230000000284 resting effect Effects 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
238000005070 sampling Methods 0.000 description 1
210000000518 sarcolemma Anatomy 0.000 description 1
208000001076 sarcopenia Diseases 0.000 description 1
238000012216 screening Methods 0.000 description 1
230000011664 signaling Effects 0.000 description 1
210000002027 skeletal muscle Anatomy 0.000 description 1
230000022379 skeletal muscle tissue development Effects 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 1
239000007787 solid Substances 0.000 description 1
229940031439 squalene Drugs 0.000 description 1
TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 1
238000010186 staining Methods 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
150000003431 steroids Chemical class 0.000 description 1
230000004936 stimulating effect Effects 0.000 description 1
230000035882 stress Effects 0.000 description 1
239000000126 substance Substances 0.000 description 1
210000003523 substantia nigra Anatomy 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
230000036561 sun exposure Effects 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
230000005737 synergistic response Effects 0.000 description 1
239000003826 tablet Substances 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
108090000721 thyroid hormone receptors Proteins 0.000 description 1
210000001578 tight junction Anatomy 0.000 description 1
238000005891 transamination reaction Methods 0.000 description 1
238000013518 transcription Methods 0.000 description 1
230000035897 transcription Effects 0.000 description 1
210000003854 type 2 muscle cell Anatomy 0.000 description 1
210000001364 upper extremity Anatomy 0.000 description 1
230000003827 upregulation Effects 0.000 description 1
210000004509 vascular smooth muscle cell Anatomy 0.000 description 1
210000003462 vein Anatomy 0.000 description 1
235000019195 vitamin supplement Nutrition 0.000 description 1
238000005303 weighing Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
- A23L33/155—Vitamins A or D
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/06—Anabolic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Nutrition Science (AREA)
Food Science & Technology (AREA)
Mycology (AREA)
Polymers & Plastics (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Physical Education & Sports Medicine (AREA)
Neurology (AREA)
Orthopedic Medicine & Surgery (AREA)
Endocrinology (AREA)
Obesity (AREA)
Hematology (AREA)
Diabetes (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

ES09832494.0T 2008-12-09 2009-12-09 Intervención nutricional para mejorar la función y resistencia muscular Active ES2689700T3 (es)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US12106508P	2008-12-09	2008-12-09
US121065P		2008-12-09
PCT/US2009/067382 WO2010068696A1 (en)	2008-12-09	2009-12-09	Nutritional intervention for improving muscular function and strength

Publications (1)

Publication Number	Publication Date
ES2689700T3 true ES2689700T3 (es)	2018-11-15

Family

ID=42243059

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ES09832494.0T Active ES2689700T3 (es)	2008-12-09	2009-12-09	Intervención nutricional para mejorar la función y resistencia muscular

Country Status (9)

Country	Link
US (1)	US8815280B2 (pl)
EP (2)	EP3403516A1 (pl)
CA (1)	CA2746420C (pl)
DK (1)	DK2381784T3 (pl)
ES (1)	ES2689700T3 (pl)
HU (1)	HUE039841T2 (pl)
PL (1)	PL2381784T3 (pl)
PT (1)	PT2381784T (pl)
WO (1)	WO2010068696A1 (pl)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20050215640A1 (en) *	2004-03-26	2005-09-29	Baxter Jeffrey H	HMB compositions and uses thereof
CN102225060A (zh)	2005-12-19	2011-10-26	雅培制药有限公司	β-羟基-β-甲基丁酸盐在调节1-型和2-型细胞因子生成失衡中的应用
US9770424B2 (en) *	2008-12-09	2017-09-26	Metabolic Technologies, Inc.	Nutritional intervention for improving muscular function and strength
US11173167B2 (en) *	2008-12-09	2021-11-16	Metabolic Technologies, Inc.	Nutritional intervention for improving muscular function and strength
US9259430B2 (en) *	2008-12-09	2016-02-16	Metabolic Technologies, Inc.	Nutritional intervention for improving muscular function and strength
US9539224B2 (en) *	2008-12-09	2017-01-10	Metabolic Technologies, Inc.	Nutritional intervention for improving muscular function and strength
US9707241B2 (en) *	2008-12-09	2017-07-18	Metabolic Technologies, Inc.	Nutritional intervention for improving muscular function and strength
WO2011075741A1 (en) *	2009-12-18	2011-06-23	Metabolic Technologies, Inc.	Improved method of administering beta-hydroxy-beta-methylbutyrate (hmb)
US8916217B2 (en)	2010-01-29	2014-12-23	Abbott Laboratories	Aseptically packaged nutritional liquids comprising HMB
US9693577B2 (en)	2010-01-29	2017-07-04	Abbott Laboratories	Method of preparing a nutritional powder comprising spray dried HMB
PE20121729A1 (es)	2010-01-29	2013-01-16	Abbott Lab	Emulsiones nutricionales que comprenden beta-hidroxi-beta-metilbutirato (hmb) de calcio
TWI526161B (zh) *	2010-06-10	2016-03-21	亞培公司	包含鈣ｈｍｂ及可溶性蛋白質之實質上透明營養液
CA2821312A1 (en) *	2010-12-27	2012-07-05	Abbott Laboratories	Methods for facilitating muscle recovery after a period of disuse using beta-hydroxy-beta-methylbutyrate
WO2012097061A1 (en) *	2011-01-13	2012-07-19	Abbott Laboratories	Nutritional compositions and methods for improving skeletal muscle protein metabolism
EP2675298A1 (en) *	2011-02-17	2013-12-25	Abbott Laboratories	Methods for improving brain development and cognitive function using beta-hydroxy-beta-methylbutyrate
US9327001B2 (en)	2011-11-03	2016-05-03	University Of Florida Research Foundation, Inc.	Nutritional supplement for weight management
US20140156297A1 (en) *	2012-08-03	2014-06-05	Axelacare Holdings, Inc.	Computer program, method, and system for pharmacist-assisted treatment of patients
US20140039907A1 (en) *	2012-08-03	2014-02-06	AxelaCare Health Solutions, Inc.	Computer program, method, and system for collecting patient data with a portable electronic device
HUE065064T2 (hu) *	2012-09-10	2024-05-28	Metabolic Tech Llc	HMB-t éa ATP-t tartalmazó készítmények és felhasználásuk
CN104619198A (zh) *	2012-09-17	2015-05-13	雅培制药有限公司	含有β-羟基-β-甲基丁酸的组合物及其用途
MX367861B (es) *	2012-10-04	2019-09-09	Abbott Lab	Una composición nutricional para usarse en la preservación del músculo esquelético.
AU2014386220B2 (en)	2013-03-14	2018-04-26	Metabolic Technologies, Inc.	Liquids and foodstuffs containing beta-hydroxy-beta-methylbutyrate (HMB) in free acid form
WO2015094772A1 (en) *	2013-12-18	2015-06-25	Abbott Laboratories	Methods for increasing skeletal muscle protein synthesis using green tea extract
EP3122348B1 (en)	2014-03-27	2020-05-27	Winterfield, Roland, W.	Beta-hydroxy beta-methylbutyrate for alleviating statin myopathy
US20160184248A1 (en) *	2014-12-15	2016-06-30	University Of Central Florida Research Foundation Inc.	Compositions and methods of use of -hydroxy-methylbutyrate (hmb) resulting in an acute endocrine response
CN107847759A (zh) *	2015-06-01	2018-03-27	代谢科技有限公司	用于减少脂肪量的β‑羟基‑β‑甲基丁酸(HMB)的组合物和使用方法
JP2019531748A (ja) *	2016-10-21	2019-11-07	メタボリック・テクノロジーズ，インコーポレーテッド	β−ヒドロキシ−β−メチルブチレート（ＨＭＢ）およびプロバイオティックを使用する組成物および方法
US10888576B2 (en)	2018-10-08	2021-01-12	Metabolic Technologies, Inc.	Composition of HMB and ATP and methods of use
WO2020200952A1 (en)	2019-04-02	2020-10-08	Evonik Operations Gmbh	Process for preparing 3-hydroxy-3-methylbutyrate (hmb) and salts thereof
JP2021070643A (ja) *	2019-10-30	2021-05-06	小林製薬株式会社	筋肉量改善用組成物
BR112022025819A2 (pt) *	2020-06-17	2023-03-07	Metabolic Tech Llc	Métodos para aumentar a massa muscular, para aumentar a força e para aprimorar a função muscular de um ser humano que não se exercita
EP3951016A1 (en)	2020-08-05	2022-02-09	Evonik Operations GmbH	Method for preparing 3-hydroxy-3-methylbutyric acid (hmb) or salts thereof
CA3206564A1 (en) *	2021-01-28	2022-08-04	Jose Maria Lopez Pedrosa	Methods and nutritional compositions for improving muscle energy production and/or strength
WO2022212621A1 (en) *	2021-03-31	2022-10-06	Abbott Laboratories	Methods and compositions for improving insulin production and secretion
WO2022225786A1 (en) *	2021-04-22	2022-10-27	Abbott Laboratories	Methods and compositions for improving muscle strength and/or reducing muscle loss

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5087472A (en)	1990-01-30	1992-02-11	Iowa State University Research Foundation, Inc.	Feed compositions for domestics animals containing hydroxymethylbutyrate
US5028440A (en)	1990-01-30	1991-07-02	Iowa State University Research Foundation, Inc.	Method of raising meat producing animals to increase lean tissue development
US4992470A (en)	1990-02-08	1991-02-12	Iowa State University Research Foundation, Inc.	Method of enhancing immune response of mammals
JPH03256371A (ja) *	1990-03-06	1991-11-15	Eastman Kodak Japan Kk	発光ダイオード及びそのアレイ
BR9307035A (pt)	1992-09-16	1999-06-29	Univ Iowa State Res Found Inc	Processo para redução dos níveis sanguíneos de colesterol total e de colesterol de lipoproteína de baixa densidade
US5348979A (en)	1992-12-23	1994-09-20	Iowa State University Research Foundation Inc.	Method of promoting nitrogen retention in humans
US6103764A (en)	1997-11-07	2000-08-15	Iowa State University Research Foundation, Inc.	Method for increasing the aerobic capacity of muscle
US6031000A (en) *	1998-06-23	2000-02-29	Iowa State University Research Foundation, Inc.	Composition comprising β-hydroxy-β-methylbutyric acid and at least one amino acid and methods of use
US6291525B1 (en)	1999-09-08	2001-09-18	Iowa State University Research Foundation, Inc.	Method for improving a human's perception of his emotional state
US7445807B2 (en) *	2002-10-15	2008-11-04	Western Holdings, Llc	Agglomerated granular protein-rich nutritional supplement
US20050215640A1 (en)	2004-03-26	2005-09-29	Baxter Jeffrey H	HMB compositions and uses thereof
US7887852B2 (en) *	2005-06-03	2011-02-15	Soft Gel Technologies, Inc.	Soft gel capsules containing polymethoxylated flavones and palm oil tocotrienols
CN102225060A (zh)	2005-12-19	2011-10-26	雅培制药有限公司	β-羟基-β-甲基丁酸盐在调节1-型和2-型细胞因子生成失衡中的应用
DK2054049T3 (en)	2006-08-24	2016-08-01	Univ Tennessee Res Found	SUBSTITUTED ACYLANILIDES AND PROCEDURES FOR USING THEREOF

2009
- 2009-12-09 PT PT09832494T patent/PT2381784T/pt unknown
- 2009-12-09 ES ES09832494.0T patent/ES2689700T3/es active Active
- 2009-12-09 US US12/634,507 patent/US8815280B2/en active Active
- 2009-12-09 EP EP18174311.3A patent/EP3403516A1/en active Pending
- 2009-12-09 HU HUE09832494A patent/HUE039841T2/hu unknown
- 2009-12-09 EP EP09832494.0A patent/EP2381784B1/en active Active
- 2009-12-09 CA CA2746420A patent/CA2746420C/en active Active
- 2009-12-09 PL PL09832494T patent/PL2381784T3/pl unknown
- 2009-12-09 WO PCT/US2009/067382 patent/WO2010068696A1/en active Application Filing
- 2009-12-09 DK DK09832494.0T patent/DK2381784T3/en active

Also Published As

Publication number	Publication date
US8815280B2 (en)	2014-08-26
WO2010068696A1 (en)	2010-06-17
EP2381784A4 (en)	2013-10-16
EP2381784A1 (en)	2011-11-02
PL2381784T3 (pl)	2019-01-31
EP2381784B1 (en)	2018-07-11
CA2746420A1 (en)	2010-06-17
US20100179112A1 (en)	2010-07-15
EP3403516A1 (en)	2018-11-21
DK2381784T3 (en)	2018-10-22
PT2381784T (pt)	2018-10-30
HUE039841T2 (hu)	2019-02-28
CA2746420C (en)	2019-11-12

Publication	Publication Date	Title
ES2689700T3 (es)	2018-11-15	Intervención nutricional para mejorar la función y resistencia muscular
US11547713B2 (en)	2023-01-10	Nutritional intervention for improving muscular function and strength
AU2014236004B2 (en)	2018-10-25	Compositions and methods for producing elevated and sustained ketosis
Dirks-Naylor et al.	2011	The effects of vitamin D on skeletal muscle function and cellular signaling
US9259430B2 (en)	2016-02-16	Nutritional intervention for improving muscular function and strength
Bouillanne et al.	2014	Long-lasting improved amino acid bioavailability associated with protein pulse feeding in hospitalized elderly patients: A randomized controlled trial
US20170106004A1 (en)	2017-04-20	Nutritional Intervention for Improving Muscular Function and Strength
US11173167B2 (en)	2021-11-16	Nutritional intervention for improving muscular function and strength
US9770424B2 (en)	2017-09-26	Nutritional intervention for improving muscular function and strength
Ceglia et al.	2018	Vitamin D and muscle performance in athletes
US20230149426A1 (en)	2023-05-18	Nutritional Intervention for Improving Muscular Function and Strength
US20210393559A1 (en)	2021-12-23	Compositions and Methods of Use of Beta-Hydroxy-Beta-methylbutyrate (HMB) for Improving Muscle Mass, Strength and Muscular Function Without Exercise
US20160184248A1 (en)	2016-06-30	Compositions and methods of use of -hydroxy-methylbutyrate (hmb) resulting in an acute endocrine response
Domingues-Faria et al.	2019	Vitamin D Signaling and Skeletal Muscle Cells
US20210113501A1 (en)	2021-04-22	Method of administering beta-hydroxy-beta-methylbutyrate (hmb)
Landi et al.	2021	Beta‐hydroxy‐beta‐methylbutyrate (HMB) and Sarcopenia
Jeukendrup et al.	2011	Exercise Performance
WO2014151128A1 (en)	2014-09-25	Composition and method for treating neuropathy
Sébastien et al.	0	MENOPAUSE AND SARCOPENIA: DIETARY AND NUTRITIONAL ASPECTS